SHARE-BASED COMPENSATION (Details) |
6 Months Ended |
|---|---|
|
Jun. 30, 2026
$ / shares
shares
| |
| Retirement Benefits [Abstract] | |
| Number of nonvested restricted shares | shares | 4,489,726 |
| Weighted average FV per ordinary share on the grant date beginning | $ / shares | $ 2.81 |
| Granted | shares | |
| Granted | $ / shares | |
| Vested | shares | (476,207) |
| Vested | $ / shares | $ 2.92 |
| Number of nonvested restricted shares | shares | 4,013,519 |
| Weighted average FV per ordinary share on the grant date ending | $ / shares | $ 2.80 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Net number of share options (or share units) granted during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of non-vested options outstanding. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of non-vested options outstanding. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|